As new drugs and combinations gain approvals for a broad range of malignancies, there is a growing need for disease-specific recommendations to help guide the integration of immunotherapy treatments into current practice.
Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.
Lynette M. Sholl, MD, discusses advancements in molecular diagnostics that have led to the development of numerous single-gene assays for the detection of genetic mutations that can be targeted in the treatment of cancers.
Although there are no drugs yet that target TP53 mutations in any tumor type, a recent analysis of a non–small cell lung cancer (NSCLC) sample set raises the prospect that a more detailed understanding of this aberration could eventually help direct therapy.
For the first time, Physicians’ Education Resource (PER®) will host 2 European conferences, providing more opportunities for oncology professionals worldwide to learn and collaborate with leading experts in the fields.
A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.